Aminopterin - Syntrix Biosystems

Drug Profile

Aminopterin - Syntrix Biosystems

Alternative Names: Aminotrexate; LD-aminopterin; Rac-aminopterin

Latest Information Update: 12 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Developer Syntrix Biosystems
  • Class Benzamides; Glutamates; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Psoriasis
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma; Rheumatoid arthritis

Most Recent Events

  • 01 Oct 2018 Phase-II clinical trials in Psoriasis in USA (PO) (NCT03431974)
  • 24 Jun 2018 Biomarkers information updated
  • 03 Aug 2015 Phase-II development is ongoing for Psoriasis and Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top